Fetal Fibronectin (fFN) testing helps clinicians to determine if a pregnant person who may be at risk of pre-term birth should be admitted to hospital and/or transferred to a high-risk perinatal unit. Evaluation of the testing protocol revealed significant cost savings to health provider organizations and the system as a whole, and suggested increased quality and safety of care to birthing individuals and their newborns.